Mechelen, Belgium; 29 June 2010 - Galapagos NV (Euronext: GLPG) issued a
correction regarding a transparency notification received on 28 June 2010,
pursuant to the Belgian transparency legislation (Belgian Act of 2 May 2007)
concerning major holdings in Belgian listed companies.
The notification received on 28 June 2010 was submitted on behalf of Mr. A.
Strating, TWE Beheer, TWE Investment, and Gestion Deelnemingen IV (not Gestion
Deelnemingen V as erroneously stated in the press release on 28 June 2010) who
declared a combined holding of 1,252,550 shares (5.2%) of Galapagos. This
shareholding is separate from the 1,184,602 shares (5.0%) held by Gestion
Deelnemingen V.
Major shareholders of Galapagos NV as of 29 June 2010:
+-----------------------------------------+----------------+-------------------+
|Shareholder |Number of shares|Percentage of total|
+-----------------------------------------+----------------+-------------------+
|Delta Lloyd Levensverzekering NV | 2,857,750 | 12.0% |
+-----------------------------------------+----------------+-------------------+
|Abingworth Management Limited | 1,576,327 | 6.6% |
+-----------------------------------------+----------------+-------------------+
|Mr. A. Strating, TWE Beheer BV, TWE | 1,252,550 | 5.2% |
|Investment BV, Gestion Deelnemingen IV BV| | |
+-----------------------------------------+----------------+-------------------+
|Crucell Holland BV | 1,236,097 | 5.2% |
+-----------------------------------------+----------------+-------------------+
|Gestion Deelnemingen V BV | 1,184,602 | 5.0% |
+-----------------------------------------+----------------+-------------------+
|Johnson & Johnson | 1,113,964 | 4.7% |
+-----------------------------------------+----------------+-------------------+
|GlaxoSmithKline | 513,281 | 2.1% |
+-----------------------------------------+----------------+-------------------+
|Insiders | 354,426 | 1.5% |
+-----------------------------------------+----------------+-------------------+
|Other shareholders | 13,801,041 | 57.7% |
+-----------------------------------------+----------------+-------------------+
|TOTAL | 23,890,038 | 100% |
+-----------------------------------------+----------------+-------------------+
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company
specialized in the discovery and development of small molecule and antibody
therapies with novel modes-of-action. The Company is progressing one of the
largest pipelines in biotech, with four clinical and over 50 small molecule
discovery/pre-clinical programs. Through risk/reward-sharing alliances with
GlaxoSmithKline, Eli Lilly, Janssen Pharmaceutica, Merck & Co. and Roche,
Galapagos is eligible to receive up to ?3 billion in downstream milestones, plus
royalties. Together with its BioFocus and Argenta service operations, Galapagos
has over 670 employees and operates facilities in six countries, with global
headquarters in Mechelen, Belgium. More info at: www.glpg.com
CONTACT
Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
ir@glpg.com
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir@glpg.com
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks, uncertainties
and other factors which might cause the actual results, financial condition,
performance or achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial conditions, performance
or achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.
[HUG#1428310]
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: Galapagos NV via Thomson Reuters ONE
